Clinical Trials Logo
  1. Home
  2. Glomerulonephritis, Membranous
  3. NCT01282073

Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy — MMFPRIMER  

Glomerulonephritis, Membranous Clinical Trial

Official title:
A Randomized Controlled Multi-center Trial of Mycophenolate Mofetil for the Patient With High Risk Membranous Nephropathy

Clinical Trial Summary

Cyclosporin decreases proteinuria and improve renal function in patients with idiopathic membranous nephropathy, but has a risk of side effects such as nephrotoxicity. The investigators plan to the study to evaluate whether mycophenolate mofetil (MMF) could be a reasonable alternative with fewer side effect.

Clinical Trial Description

Idiopathic membranous nephropathy is most common cause of glomerulonephritis in adults. Persistent high grade proteinuria or progressively decrease of renal function is a risk factor for end stage renal disease in idiopathic membranous nephropathy. It has been reported that cyclosporin in patients with idiopathic membranous nephropathy decreases proteinuria and improve renal function. Mycophenolate mofetil is a recently developed immunosuppressive agent with fewer side effect than cyclosporin. In this study patients with high risk group of progressive idiopathic membranous nephropathy will be treated with mycophenolate mofetil and low dose prednisone. The outcome will be compared to controls treated with cyclosporin and low dose prednisone. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01282073
Study type Interventional
Source Kyungpook National University
Contact Hee-Yeon Jung, MD
Phone +82-10-2536-4106
Email 83mayring@hanmail.net
Status Recruiting
Phase Phase 3
Start date March 2011
Completion date July 2017
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01129557 - Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease Phase 4
Completed NCT00199628 - Research Network for Neonatal Diseases Induced by Tissular Fetomaternal Alloimmunization
Active, not recruiting NCT05656963 - The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
Completed NCT04145440 - Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) Phase 1/Phase 2
Terminated NCT04154787 - Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy Phase 2
Completed NCT00404794 - A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis Phase 3
Completed NCT03880643 - Rituximab in Refractory Primary Membranous Nephropathy
Not yet recruiting NCT05797051 - Application of Hyperspectral Imaging in the Diagnosis of Glomerular Diseases
Completed NCT00135967 - Mycophenolate Mofetil in Membranous Nephropathy Phase 2/Phase 3
Completed NCT00843856 - Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis Phase 4
Recruiting NCT05914155 - Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy With Nephrotic Syndrome Phase 3
Completed NCT00135954 - Treatment of Patients With Idiopathic Membranous Nephropathy Phase 3
Completed NCT01610492 - A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy Phase 2
Active, not recruiting NCT03018535 - Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy Phase 3
Completed NCT00404833 - Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental Phase 3
Withdrawn NCT01762852 - Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy Phase 2